Research ArticleExperimental Studies
Open Access

Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal Fibroblasts

SEI MORINAGA, QINGHONG HAN, KOHEI MIZUTA, BYUNG MO KANG, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA and ROBERT M. HOFFMAN
Anticancer Research December 2024, 44 (12) 5207-5213; DOI: https://doi.org/10.21873/anticanres.17347

Abstract

Background/Aim: Docetaxel combined with gemcitabine is a second-line treatment for soft-tissue sarcoma; however, its effectiveness is limited because of docetaxel resistance. The objective of the present study was to determine the potential of recombinant methioninase (rMETase) to enhance the efficacy of docetaxel on high-docetaxel-resistant human fibrosarcoma cells in vitro. Materials and Methods: Docetaxel-resistant HT1080 (DTR-HT1080) human fibrosarcoma cells were established by culturing them in by progressively increasing concentrations of docetaxel from 0.02 to 9 nM in vitro. The IC50 values for docetaxel and rMETase, as well as the efficacy of their combination, in inhibiting HT1080 human fibrosarcoma cells, DTR-HT1080 cells, and Hs27 normal human fibroblasts were determined. Four experimental groups were examined in vitro: control group without treatment; docetaxel alone; rMETase alone; docetaxel combined with rMETase. Results: The IC50 of docetaxel for DTR-HT1080 cells was 7.57 nM, compared to the parental HT1080 cells with an IC50 of 1.68 nM, a 4.5-fold increase. The IC50 of docetaxel on Hs27 fibroblasts was 4.46 nM. The IC50 of rMETase on HT1080 cells was 0.75 U/ml (data from [6]). The IC50 of rMETase on DTR-HT1080 cells was 0.55 U/ml. The IC50 of rMETase on Hs27 fibroblasts was 0.93 U/ml (data from [6]). Docetaxel (1.68 nM [IC50]) plus rMETase (0.75 U/ml [IC50]) synergistically reduced the viability of HT1080 cells (p<0.05). In contrast, docetaxel (4.46 nM) plus rMETase (0.93 U/ml) did not reduce the viability of Hs27 fibroblasts, compared to either agent alone. The combination of rMETase (0.55 U/ml [IC50]) and docetaxel (1.68 nM [IC50 of the parental cells]) overcame docetaxel resistance of DTR-HT1080 cells, resulting in an inhibition of 48.1% compared to docetaxel alone (6.8%) or rMETase alone (37.5%) (p<0.05). rMETase thus increased the efficacy of docetaxel 7-fold on docetaxel-resistant human fibrosarcoma cells. Conclusion: The combination of docetaxel and rMETase was synergistic on HT1080 fibrosarcoma cells, but not normal fibroblasts. rMETase plus docetaxel synergistically reduced the high docetaxel resistance of DTR-HT1080 cells. The present results indicate the clinical potential of rMETase to reduce docetaxel resistance in soft-tissue sarcoma patients in the future.

Key Words:

A promising therapeutic approach for advanced soft-tissue sarcoma has been the concurrent administration of docetaxel and gemcitabine as second-line therapy (1). However, efficacy is limited by the onset of docetaxel resistance. One large clinical trial involving the combination therapy of gemcitabine and docetaxel demonstrated an overall response rate of only 18.4% and a median overall survival period of only 12.1 months (2).

Methionine addiction of cancer, also known as the Hoffman Effect is a fundamental and universal hallmark of cancer (3, 4). Multiple studies have shown that due to their synergistic efficacy, recombinant methioninase (rMETase), or a methionine-free medium, or a diet low in methionine, all of which target methionine addiction of cancer, improve the efficacy of chemotherapy of major cancer types, both in vitro, in mouse models, and in clinical settings (5-23).

The present study determined whether rMETase could enhance the efficacy of docetaxel on highly-docetaxel-resistant (DTR) HT1080 fibrosarcoma cells.

Materials and Methods

Cell culture. HT1080 human fibrosarcoma cells were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). HT1080 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with the addition of 10% fetal bovine serum (FBS) and 1 IU/ml penicillin/streptomycin (10-013-CV; Corning, Corning, NY, USA).

Reagents. Docetaxel was obtained from Accord Healthcare Inc. (Durham, NC, USA). Recombinant methioninase (rMETase) was produced by AntiCancer Inc. (San Diego, CA, USA) as previously described (24).

Establishment of docetaxel-resistant HT1080 cells (DTR-HT1080). HT1080 human fibrosarcoma cells were cultured stepwise in progressively higher concentrations of docetaxel, ranging from 0.02 to 9 nM over a period of five months.

Drug sensitivity assay 1: Determination of the IC50 of docetaxel and rMETase on HT1080 cells, DTR-HT1080 cells, and Hs27 normal fibroblasts. Cell viability was determined with the WST-8 reagent (Dojindo Laboratory, Kumamoto, Japan). HT1080, DTR-HT1080 cells, and Hs27 normal fibroblasts were grown in 96-well dishes, with 3×103 cells per well, in Dulbecco’s modified Eagle’s medium (DMEM) (100 μl per well), and were incubated for several hours. rMETase (0.5 U/ml to 8 U/ml) or docetaxel (1 nM to 16 nM) were added to the cells for 72 h. At the end of the culture period, 10 μl of the WST-8 solution was added to each well. Subsequently, the dish was incubated for 1 h at 37°C. Absorption was measured at 450 nm with a microplate reader (SUNRISE: TECAN, Mannedorf, Switzerland). Microsoft Excel for Mac 2016 version 15.52 (Microsoft, Redmond, WA, USA) was used to generate drug-sensitivity curves. ImageJ version 1.53k (National Institutes of Health, Bethesda, MD, USA) was used to determine half-maximal inhibitory concentration (IC50) values. Each experiment was conducted twice in triplicate.

Drug sensitivity assay 2: Determination of synergy of docetaxel and rMETase on HT1080 human fibrosarcoma cells, DTR-HT1080 cells, and Hs27 normal fibroblasts. HT1080, DTR-HT1080 cells or Hs27 fibroblasts were seeded in 96-well plates at a density of 3×103 cells per well. Each cell line was treated with single agents as follows 24 h later: untreated control (DMEM); docetaxel alone (1.68 nM) for HT1080 cells and DTR-HT1080 cells or 4.46 nM for Hs27 fibroblasts; rMETase alone (0.75 U/ml) for HT1080 cells, 0.55 U/ml for DTR-HT1080 cells or 0.93 U/ml for Hs27 fibroblasts. For the drug combination experiments the cells were treated as follows: docetaxel (1.68 nM) for HT1080 cells or DTR-HT1080 cells or 4.46 nM for Hs27 fibroblasts, plus rMETase (0.75 U/ml) for HT1080 cells, 0.55 U/ml for DTR-HT1080 cells or 0.93 U/ml for Hs27 fibroblasts. The viability of the cells was evaluated 72 h later, as described above.

Statistical analysis. EZR software (Jichi Medical University, Saitama, Japan) was used for statistical analyses (25). Tukey–Kramer analysis was used to analyse the relationship between variables. p≤0.05 was considered statistically significant.

Results

IC50 of docetaxel alone and rMETase alone on HT1080 cells, DTR-HT1080 cells, and Hs27 normal fibroblasts. The IC50 value of docetaxel alone on HT1080 cells was 1.68 nM. The IC50 of docetaxel alone on DTR-HT1080 cells was 7.57 nM, a 4.5-fold increase of resistance. The IC50 of docetaxel alone on Hs27 fibroblasts was 4.46 nM. The IC50 for rMETase alone on HT1080 cells was 0.75 U/ml [data from (6)] and the IC50 of rMETase alone on DTR-HT1080 cells was 0.55 U/ml. The IC50 for rMETase alone on Hs27 fibroblasts was 0.93 U/ml [data from (6)]. These results demonstrate the efficacy of rMETase alone on DTR-HT1080 was similar to that on HT1080 cells (Figure 1).

Figure 1.
Figure 1.

Docetaxel and rMETase sensitivity of HT1080 fibrosarcoma cells, docetaxel-resistant HT1080 (DTR-HT1080) cells, and Hs27 normal fibroblasts (mean±standard deviation). A) Sensitivity of HT1080 cells to docetaxel. B) Sensitivity of HT1080 cells to rMETase [data from (6)]. C) Sensitivity of DTR-HT1080 cells to docetaxel. D) Sensitivity of DTR-HT1080 cells to rMETase. E) Sensitivity of Hs27 cells to docetaxel. F) Sensitivity of Hs27 cells to rMETase [data from (6)].

Synergy of rMETase plus docetaxel on HT1080 fibrosarcoma cells and DTR-HT1080 cells, but not on Hs27 fibroblasts. Docetaxel [1.68 nM (IC50 on HT1080 cells)] plus rMETase [0.75 U/ml (IC50 on HT1080 cells)] synergistically reduced the viability of HT1080 cells (p<0.05). In contrast, docetaxel [4.46 nM (IC50 on Hs27 cells)] plus rMETase [(0.93 U/ml (IC50 on Hs27 cells)] did not reduce the viability of Hs27 fibroblasts, compared to either agent alone. The combination of rMETase [0.55 U/ml (IC50 on DTR-HT1080 cells)] and docetaxel [1.68 nM (IC50 on HT1080 cells)] reduced the docetaxel resistance of DTR-143B cells, resulting in an inhibition of 48.1% compared to docetaxel alone (6.8%) or rMETase alone (37.5%) (p<0.05). rMETase thus increased the efficacy of docetaxel 7-fold on DTR-HT1080 cells by reducing docetaxel resistance of DTR-HT1080 (Figure 2).

Figure 2.
Figure 2.

Efficacy of the combination of docetaxel plus rMETase on HT1080 fibrosarcoma cells, Hs27 normal human fibroblasts, and DTR-HT1080 cells. A) HT1080 cells: Control (DMEM); docetaxel [1.68 nM (IC50 for HT1080 cells)]; rMETase [0.75 U/ml (IC50 for HT1080 cells)]; docetaxel [1.68 nM (IC50 for HT1080 cells)] plus rMETase [0.75 U/ml (IC50 for HT1080 cells)]. B) Hs27 normal human fibroblasts: Control (DMEM); docetaxel [4.46 nM (IC50 for Hs27 fibroblasts)]; rMETase [0.93 U/ml (IC50 for Hs27 fibroblasts)]; docetaxel [4.46 nM (IC50 for Hs27 fibroblasts)] plus rMETase [0.93 U/ml [IC50 for Hs27 fibroblasts)]. C) DTR-HT1080 cells: Control (DMEM); docetaxel [1.68 nM (IC50 for HT1080 cells)]; rMETase [0.55 U/ml (IC50 for DTR-HT1080 cells)]; docetaxel [1.68 nM (IC50 for HT1080 cells)] plus rMETase [0.55 U/ml (IC50 for DTR-HT1080 cells)].

Discussion

In a clinical study of docetaxel alone on anthracycline- and ifosfamide-resistant advanced soft tissue sarcoma, median progression-free survival and overall survival were 2.4 and 7.7 months, respectively (26). In another study of docetaxel alone for soft tissue sarcoma, resistant to at least one anthracycline-containing regimen, the median progression-free survival was 1.4 months, while the median overall survival was 11.7 months (27). Though the combination of docetaxel and gemcitabine has been used for second-line chemotherapy of soft-tissue sarcoma, the effect is limited due to the onset of docetaxel resistance. In clinical studies of the combination of docetaxel and gemcitabine for advanced soft-tissue sarcoma, the median overall survival was only 10.3-14.2 months and progression-free survival was only 3-3.3 months (1, 28).

In the present study, the combination of rMETase and docetaxel resulted in a 7-fold increase in efficacy on DTR-HT1080 cells compared to docetaxel alone. The combination of rMETase and docetaxel has clinical potential for soft tissue sarcoma patients.

We have previously shown that rMETase sensitized osteosarcoma to methotrexate, docetaxel, and cisplatinum in patient-derived orthotopic xenograft (PDOX) mouse models (29-31), and sensitized soft tissue sarcoma to doxorubicin in PDOX mouse models (32-38). We have also recently shown that rMETase sensitized drug-resistant soft-tissue sarcoma cells to eribulin, trabectedin, and doxorubicin (12, 14, 15). Recently we showed that rMETase sensitized androgen-resistant prostate carcinoma cells to docetaxel (39).

It is a challenge to minimize damage of chemotherapy on normal cells and kill chemotherapy-resistant cells (40). In the present study, the combination of docetaxel plus rMETase had synergy on HT1080 and DTR-HT1080 cells but not Hs27 normal fibroblasts. We have recently shown that the combination of rMETase plus docetaxel could overcome docetaxel resistance of osteosarcoma cells (41).

The present results suggest that rMETase in combination with docetaxel has clinical potential for soft-tissue sarcoma patients who have developed docetaxel resistance, a major clinical problem.

rMETase is effective because it targets the fundamental basis of cancer, methionine addiction, known as the Hoffman Effect (42-64).

rMETase is synergistic with chemotherapy (13) because it selectively arrests cancer cells in the late S/G2-phase of the cell cycle, which chemotherapy targets (65-67).

rMETase is now showing early clinical potential (8, 16, 18-23).

Acknowledgements

This article is dedicated to the memory of A.R. Moossa, MD, Sun Lee, MD, Professor Gordon H. Sato, Professor Li Jiaxi, Masaki Kitajima, MD, Joseph R. Bertino, MD, Shigeo Yagi, PhD, J.A.R Mead, PhD, Eugene P. Frenkel, MD, Professor Lev Bergelson, Professor Sheldon Penman, Professor John R. Raper, Joseph Leighton, MD and John Mendelsohn, MD. The Robert M. Hoffman Foundation for Cancer Research provided funds for the present study.

Footnotes

  • Authors’ Contributions

    SM, RMH, and QH designed the study. QH provided rMETase. SM performed experiments. SM was the major contributor to writing the article and RMH revised the article. KM, BMK, MB, NY, KH, HK, SM, KI, TH, HT, and SD critically read the manuscript.

  • Conflicts of Interest

    The Authors have declared that there are no competing interests in relation to this study.

  • Received September 22, 2024.
  • Revision received October 13, 2024.
  • Accepted October 14, 2024.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Kim JH,
    2. Park HS,
    3. Heo SJ,
    4. Kim SK,
    5. Han JW,
    6. Shin K-H,
    7. Kim SH,
    8. Hur H,
    9. Kim KS,
    10. Choi YD,
    11. Kim S,
    12. Lee YH,
    13. Suh J-S,
    14. Ahn J-B,
    15. Chung HC,
    16. Noh SH,
    17. Rha SY,
    18. Kim HS
    : Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma. Oncology 96(2): 59-69, 2019. DOI: 10.1159/000492597
    OpenUrlCrossRefPubMed
  2. ↵
    1. Bay JO,
    2. Ray-Coquard I,
    3. Fayette J,
    4. Leyvraz S,
    5. Cherix S,
    6. Piperno-Neumann S,
    7. Chevreau C,
    8. Isambert N,
    9. Brain E,
    10. Emile G,
    11. Le Cesne A,
    12. Cioffi A,
    13. Kwiatkowski F,
    14. Coindre JM,
    15. Bui NB,
    16. Peyrade F,
    17. Penel N,
    18. Blay JY, Groupe Sarcome Français
    : Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 119(3): 706-11, 2006. DOI: 10.1002/ijc.21867
    OpenUrlCrossRefPubMed
  3. ↵
    1. Hoffman RM
    : Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther 15(1): 21-31, 2015. DOI: 10.1517/14712598.2015.963050
    OpenUrlCrossRefPubMed
  4. ↵
    1. Hoffman RM,
    2. Erbe RW
    : High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci USA 73(5): 1523-1527, 1976. DOI: 10.1073/pnas.73.5.1523
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Choobin BB,
    2. Kubota Y,
    3. Han Q,
    4. Ardjmand D,
    5. Morinaga S,
    6. Mizuta K,
    7. Bouvet M,
    8. Tsunoda T,
    9. Hoffman RM
    : Recombinant methioninase lowers the effective dose of regorafenib against colon-cancer cells: a strategy for widespread clinical use of a toxic drug. Cancer Diagn Progn 3(6): 655-659, 2023. DOI: 10.21873/cdp.10268
    OpenUrlCrossRefPubMed
  6. ↵
    1. Morinaga S,
    2. Han Q,
    3. Kubota Y,
    4. Mizuta K,
    5. Kang BM,
    6. Sato M,
    7. Bouvet M,
    8. Yamamoto N,
    9. Hayashi K,
    10. Kimura H,
    11. Miwa S,
    12. Igarashi K,
    13. Higuchi T,
    14. Tsuchiya H,
    15. Hoffman RM
    : Extensive synergy between recombinant methioninase and eribulin against fibrosarcoma cells but not normal fibroblasts. Anticancer Res 44(3): 921-928, 2024. DOI: 10.21873/anticanres.16886
    OpenUrlAbstract/FREE Full Text
    1. Ardjmand D,
    2. Kubota Y,
    3. Sato M,
    4. Han Q,
    5. Mizuta K,
    6. Morinaga S,
    7. Hoffman RM
    : Selective synergy of rapamycin combined with methioninase on cancer cells compared to normal cells. Anticancer Res 44(3): 929-933, 2024. DOI: 10.21873/anticanres.16887
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kubota Y,
    2. Han Q,
    3. Morinaga S,
    4. Tsunoda T,
    5. Hoffman RM
    : Rapid reduction of CEA and stable metastasis in an NRAS-mutant rectal-cancer patient treated with FOLFIRI and bevacizumab combined with oral recombinant methioninase and a low-methionine diet upon metastatic recurrence after FOLFIRI and bevacizumab treatment alone. In Vivo 37(5): 2134-2138, 2023. DOI: 10.21873/invivo.13310
    OpenUrlAbstract/FREE Full Text
    1. Sato M,
    2. Han Q,
    3. Kubota Y,
    4. Baranov A,
    5. Ardjmand D,
    6. Mizuta K,
    7. Morinaga S,
    8. Kang BM,
    9. Kobayashi N,
    10. Bouvet M,
    11. Ichikawa Y,
    12. Nakajima A,
    13. Hoffman RM
    : Recombinant methioninase decreased the effective dose of irinotecan by 15-fold against colon cancer cells: a strategy for effective low-toxicity treatment of colon cancer. Anticancer Res 44(1): 31-35, 2024. DOI: 10.21873/anticanres.16785
    OpenUrlAbstract/FREE Full Text
    1. Kubota Y,
    2. Aoki Y,
    3. Masaki N,
    4. Obara K,
    5. Hamada K,
    6. Han Q,
    7. Bouvet M,
    8. Tsunoda T,
    9. Hoffman RM
    : Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease. Biochem Biophys Res Commun 695: 149418, 2024. DOI: 10.1016/j.bbrc.2023.149418
    OpenUrlCrossRefPubMed
    1. Morinaga S,
    2. Han Q,
    3. Kubota Y,
    4. Mizuta K,
    5. Kang BM,
    6. Sato M,
    7. Bouvet M,
    8. Yamamoto N,
    9. Hayashi K,
    10. Kimura H,
    11. Miwa S,
    12. Igarashi K,
    13. Higuchi T,
    14. Tsuchiya H,
    15. Demura S,
    16. Hoffman RM
    : DNA-binding agent trabectedin combined with recombinant methioninase is synergistic to decrease fibrosarcoma cell viability and induce nuclear fragmentation but not synergistic on normal fibroblasts. Anticancer Res 44(6): 2359-2367, 2024. DOI: 10.21873/anticanres.17043
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Sato M,
    6. Bouvet M,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Higuchi T,
    13. Tsuchiya H,
    14. Demura S,
    15. Hoffman RM
    : Recombinant methioninase is selectively synergistic with doxorubicin against wild-type fibrosarcoma cells compared to normal cells and overcomes highly-doxorubicin-resistant fibrosarcoma. Anticancer Res 44(8): 3261-3268, 2024. DOI: 10.21873/anticanres.17144
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Kubota Y,
    2. Han Q,
    3. Aoki Y,
    4. Masaki N,
    5. Obara K,
    6. Hamada K,
    7. Hozumi C,
    8. Wong ACW,
    9. Bouvet M,
    10. Tsunoda T,
    11. Hoffman RM
    : Synergy of combining methionine restriction and chemotherapy: the disruptive next generation of cancer treatment. Cancer Diagn Progn 3(3): 272-281, 2023. DOI: 10.21873/cdp.10212
    OpenUrlCrossRefPubMed
  14. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Sato M,
    6. Bouvet M,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Higuchi T,
    13. Tsuchiya H,
    14. Demura S,
    15. Hoffman RM
    : Overcoming high trabectedin resistance of soft-tissue sarcoma with recombinant methioninase: a potential solution of a recalcitrant clinical problem. Anticancer Res 44(9): 3785-3791, 2024. DOI: 10.21873/anticanres.17203
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Sato M,
    6. Bouvet M,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Higuchi T,
    13. Tsuchiya H,
    14. Demura S,
    15. Hoffman RM
    : Recombinant methioninase increases eribulin efficacy 16-fold in highly eribulin-resistant HT1080 fibrosarcoma cells, demonstrating potential to overcome the clinical challenge of drug-resistant soft-tissue sarcoma. Anticancer Res 44(9): 3777-3783, 2024. DOI: 10.21873/anticanres.17202
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Sato M,
    2. Han Q,
    3. Mori R,
    4. Mizuta K,
    5. Kang BM,
    6. Morinaga S,
    7. Kobayashi N,
    8. Ichikawa Y,
    9. Nakajima A,
    10. Hoffman RM
    : Reduction of tumor biomarkers from very high to normal and extensive metastatic lesions to undetectability in a patient with stage IV HER2-positive breast cancer treated with low-dose trastuzumab deruxtecan in combination with oral recombinant methioninase and a low-methionine diet. Anticancer Res 44(4): 1499-1504, 2024. DOI: 10.21873/anticanres.16946
    OpenUrlAbstract/FREE Full Text
    1. Kubota Y,
    2. Sato T,
    3. Hozumi C,
    4. Han Q,
    5. Aoki Y,
    6. Masaki N,
    7. Obara K,
    8. Tsunoda T,
    9. Hoffman RM
    : Superiority of [(11)C]methionine over [(18)F]deoxyglucose for PET imaging of multiple cancer types due to the methionine addiction of cancer. Int J Mol Sci 24(3): 1935, 2023. DOI: 10.3390/ijms24031935
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kubota Y,
    2. Han Q,
    3. Masaki N,
    4. Hozumi C,
    5. Hamada K,
    6. Aoki Y,
    7. Obara K,
    8. Tsunoda T,
    9. Hoffman RM
    : Elimination of axillary-lymph-node metastases in a patient with invasive lobular breast cancer treated by first-line neo-adjuvant chemotherapy combined with methionine restriction. Anticancer Res 42(12): 5819-5823, 2022. DOI: 10.21873/anticanres.16089
    OpenUrlAbstract/FREE Full Text
    1. Kubota Y,
    2. Han Q,
    3. Hamada K,
    4. Aoki Y,
    5. Masaki N,
    6. Obara K,
    7. Tsunoda T,
    8. Hoffman RM
    : Long-term stable disease in a rectal-cancer patient treated by methionine restriction with oral recombinant methioninase and a low-methionine diet. Anticancer Res 42(8): 3857-3861, 2022. DOI: 10.21873/anticanres.15877
    OpenUrlAbstract/FREE Full Text
    1. Kubota Y,
    2. Han Q,
    3. Hozumi C,
    4. Masaki N,
    5. Yamamoto J,
    6. Aoki Y,
    7. Tsunoda T,
    8. Hoffman RM
    : Stage IV pancreatic cancer patient treated with FOLFIRINOX combined with oral methioninase: a highly-rare case with long-term stable disease. Anticancer Res 42(5): 2567-2572, 2022. DOI: 10.21873/anticanres.15734
    OpenUrlAbstract/FREE Full Text
    1. Han Q,
    2. Tan Y,
    3. Hoffman RM
    : Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methionine in a high-stage ovarian cancer patient. Anticancer Res 40(5): 2813-2819, 2020. DOI: 10.21873/anticanres.14254
    OpenUrlAbstract/FREE Full Text
    1. Sato M,
    2. Han Q,
    3. Mizuta K,
    4. Mori R,
    5. Kang BM,
    6. Morinaga S,
    7. Kobayashi N,
    8. Ichikawa Y,
    9. Nakajima A,
    10. Hoffman RM
    : Extensive shrinkage and long-term stable disease in a teenage female patient with high-grade glioma treated with temozolomide and radiation in combination with oral recombinant methioninase and a low-methionine diet. In Vivo 38(3): 1459-1464, 2024. DOI:10.21873/invivo.13591
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Sato M,
    2. Han Q,
    3. Hozumi C,
    4. Kujiraoka H,
    5. Mizuta K,
    6. Morinaga S,
    7. Kang BM,
    8. Kobayashi N,
    9. Ichikawa Y,
    10. Nakajima A,
    11. Hoffman RM
    : First-line chemotherapy in combination with oral recombinant methioninase and a low-methionine diet for a stage IV inoperable pancreatic-cancer patient resulted in 40% tumor reduction and an 86% CA19-9 biomarker decrease. Anticancer Res 44(9): 3885-3889, 2024. DOI: 10.21873/anticanres.17215
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Tan Y,
    2. Xu M,
    3. Tan X,
    4. Tan X,
    5. Wang X,
    6. Saikawa Y,
    7. Nagahama T,
    8. Sun X,
    9. Lenz M,
    10. Hoffman RM
    : Overexpression and large-scale production of recombinantl-methionine-α-deamino-γ-mercaptomethane-lyase for novel anticancer therapy. Protein Expr Purif 9(2): 233-245, 1997. DOI: 10.1006/prep.1996.0700
    OpenUrlCrossRefPubMed
  25. ↵
    1. Kanda Y
    : Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3): 452-458, 2013. DOI: 10.1038/bmt.2012.244
    OpenUrlCrossRefPubMed
  26. ↵
    1. Köstler WJ,
    2. Brodowicz T,
    3. Attems Y,
    4. Hejna M,
    5. Tomek S,
    6. Amann G,
    7. Fiebiger WC,
    8. Wiltschke CH,
    9. Krainer M,
    10. Zielinski CC
    : Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial. Ann Oncol 12(9): 1281-1288, 2001. DOI: 10.1023/a:1012272007146
    OpenUrlCrossRefPubMed
  27. ↵
    1. Santoro A,
    2. Romanini A,
    3. Rosso A,
    4. Frustaci S,
    5. Comandone A,
    6. Apice G,
    7. De Toma D,
    8. Dogliotti L,
    9. Lionetto R,
    10. Dani C,
    11. Bruzzi P,
    12. Piolini M,
    13. Bergnolo P,
    14. Verusio C
    : Lack of activity of docetaxel in soft tissue sarcomas: results of a phase II study of the Italian group on rare tumors. Sarcoma 3(3-4): 177-181, 1999. DOI: 10.1080/13577149977613
    OpenUrlCrossRefPubMed
  28. ↵
    1. Choi Y,
    2. Yun MS,
    3. Lim SH,
    4. Lee J,
    5. Ahn JH,
    6. Kim YJ,
    7. Park KH,
    8. Park YS,
    9. Lim HY,
    10. An H,
    11. Suh DC,
    12. Kim YH
    : Gemcitabine and docetaxel combination for advanced soft tissue sarcoma: a nationwide retrospective study. Cancer Res Treat 50(1): 175-182, 2018. DOI: 10.4143/crt.2016.535
    OpenUrlCrossRefPubMed
  29. ↵
    1. Aoki Y,
    2. Tome Y,
    3. Wu NF,
    4. Yamamoto J,
    5. Hamada K,
    6. Han Q,
    7. Bouvet M,
    8. Nishida K,
    9. Hoffman RM
    : Oral-recombinant methioninase converts an osteosarcoma from docetaxel-resistant to -sensitive in a clinically-relevant patient-derived orthotopic-xenograft (PDOX) mouse model. Anticancer Res 41(4): 1745-1751, 2021. DOI: 10.21873/anticanres.14939
    OpenUrlAbstract/FREE Full Text
    1. Aoki Y,
    2. Tome Y,
    3. Han Q,
    4. Yamamoto J,
    5. Hamada K,
    6. Masaki N,
    7. Kubota Y,
    8. Bouvet M,
    9. Nishida K,
    10. Hoffman RM
    : Oral-recombinant methioninase converts an osteosarcoma from methotrexate-resistant to -sensitive in a patient-derived orthotopic-xenograft (PDOX) mouse model. Anticancer Res 42(2): 731-737, 2022. DOI: 10.21873/anticanres.15531
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Higuchi T,
    2. Sugisawa N,
    3. Yamamoto J,
    4. Oshiro H,
    5. Han Q,
    6. Yamamoto N,
    7. Hayashi K,
    8. Kimura H,
    9. Miwa S,
    10. Igarashi K,
    11. Tan Y,
    12. Kuchipudi S,
    13. Bouvet M,
    14. Singh SR,
    15. Tsuchiya H,
    16. Hoffman RM
    : The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. Cancer Chemother Pharmacol 85(2): 285-291, 2020. DOI: 10.1007/s00280-019-03986-0
    OpenUrlCrossRefPubMed
  32. ↵
    1. Igarashi K,
    2. Kawaguchi K,
    3. Kiyuna T,
    4. Miyake K,
    5. Miyaki M,
    6. Yamamoto N,
    7. Hayashi K,
    8. Kimura H,
    9. Miwa S,
    10. Higuchi T,
    11. Singh AS,
    12. Chmielowski B,
    13. Nelson SD,
    14. Russell TA,
    15. Eckardt MA,
    16. Dry SM,
    17. Li Y,
    18. Singh SR,
    19. Chawla SP,
    20. Eilber FC,
    21. Tsuchiya H,
    22. Hoffman RM
    : Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. Biochem Biophys Res Commun 506(4): 912-917, 2018. DOI: 10.1016/j.bbrc.2018.10.119
    OpenUrlCrossRefPubMed
    1. Igarashi K,
    2. Kawaguchi K,
    3. Li S,
    4. Han Q,
    5. Tan Y,
    6. Murakami T,
    7. Kiyuna T,
    8. Miyake K,
    9. Miyake M,
    10. Singh AS,
    11. Eckardt MA,
    12. Nelson SD,
    13. Russell TA,
    14. Dry SM,
    15. Li Y,
    16. Yamamoto N,
    17. Hayashi K,
    18. Kimura H,
    19. Miwa S,
    20. Tsuchiya H,
    21. Singh SR,
    22. Eilber FC,
    23. Hoffman RM
    : Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. Cancer Lett 417: 168-173, 2018. DOI:10.1016/j.canlet.2017.12.028
    OpenUrlCrossRefPubMed
    1. Higuchi T,
    2. Kawaguchi K,
    3. Miyake K,
    4. Han Q,
    5. Tan Y,
    6. Oshiro H,
    7. Sugisawa N,
    8. Zhang Z,
    9. Razmjooei S,
    10. Yamamoto N,
    11. Hayashi K,
    12. Kimura H,
    13. Miwa S,
    14. Igarashi K,
    15. Chawla SP,
    16. Singh AS,
    17. Eilber FC,
    18. Singh SR,
    19. Tsuchiya H,
    20. Hoffman RM
    : Oral recombinant methioninase combined with caffeine and doxorubicin induced regression of a doxorubicin-resistant synovial sarcoma in a PDOX mouse model. Anticancer Res 38(10): 5639-5644, 2018. DOI: 10.21873/anticanres.12899
    OpenUrlAbstract/FREE Full Text
    1. Igarashi K,
    2. Li S,
    3. Han Q,
    4. Tan Y,
    5. Kawaguchi K,
    6. Murakami T,
    7. Kiyuna T,
    8. Miyake K,
    9. Li Y,
    10. Nelson SD,
    11. Dry SM,
    12. Singh AS,
    13. Elliott IA,
    14. Russell TA,
    15. Eckardt MA,
    16. Yamamoto N,
    17. Hayashi K,
    18. Kimura H,
    19. Miwa S,
    20. Tsuchiya H,
    21. Eilber FC,
    22. Hoffman RM
    : Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. J Cell Biochem 119(4): 3537-3544, 2018. DOI: 10.1002/jcb.26527
    OpenUrlCrossRefPubMed
    1. Higuchi T,
    2. Oshiro H,
    3. Miyake K,
    4. Sugisawa N,
    5. Han Q,
    6. Tan Y,
    7. Park J,
    8. Zhang Z,
    9. Razmjooei S,
    10. Yamamoto N,
    11. Hayashi K,
    12. Kimura H,
    13. Miwa S,
    14. Igarashi K,
    15. Bouvet M,
    16. Chawla SP,
    17. Singh SR,
    18. Tsuchiya H,
    19. Hoffman RM
    : Oral recombinant methioninase, combined with oral caffeine and injected cisplatinum, overcome cisplatinum-resistance and regresses patient-derived orthotopic xenograft model of osteosarcoma. Anticancer Res 39(9): 4653-4657, 2019. DOI: 10.21873/anticanres.13646
    OpenUrlAbstract/FREE Full Text
    1. Higuchi T,
    2. Han Q,
    3. Miyake K,
    4. Oshiro H,
    5. Sugisawa N,
    6. Tan Y,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Bouvet M,
    13. Singh SR,
    14. Tsuchiya H,
    15. Hoffman RM
    : Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun 523(1): 135-139, 2020. DOI: 10.1016/j.bbrc.2019.12.024
    OpenUrlCrossRefPubMed
  38. ↵
    1. Igarashi K,
    2. Kawaguchi K,
    3. Li S,
    4. Han Q,
    5. Tan Y,
    6. Gainor E,
    7. Kiyuna T,
    8. Miyake K,
    9. Miyake M,
    10. Higuchi T,
    11. Oshiro H,
    12. Singh AS,
    13. Eckardt MA,
    14. Nelson SD,
    15. Russell TA,
    16. Dry SM,
    17. Li Y,
    18. Yamamoto N,
    19. Hayashi K,
    20. Kimura H,
    21. Miwa S,
    22. Tsuchiya H,
    23. Eilber FC,
    24. Hoffman RM
    : Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget 9(27): 19263-19272, 2018. DOI: 10.18632/oncotarget.24996
    OpenUrlCrossRefPubMed
  39. ↵
    1. Mizuta K,
    2. Mori R,
    3. Han Q,
    4. Morinaga S,
    5. Sato M,
    6. Kang BM,
    7. Bouvet M,
    8. Tome Y,
    9. Nishida K,
    10. Hoffman RM
    : The combination of methionine restriction and docetaxel synergistically arrests androgen-independent prostate cancer but not normal cells. Cancer Diagn Progn 4(4): 402-407, 2024. DOI: 10.21873/cdp.10339
    OpenUrlCrossRefPubMed
  40. ↵
    1. Blagosklonny MV
    : Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells. Oncotarget 14: 193-206, 2023. DOI: 10.18632/oncotarget.28382
    OpenUrlCrossRefPubMed
  41. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Bouvet M,
    6. Yamamoto N,
    7. Hayashi K,
    8. Kimura H,
    9. Miwa S,
    10. Igarashi K,
    11. Higuchi T,
    12. Tsuchiya H,
    13. Demura S,
    14. Hoffman RM
    : recombinant methioninase synergistically reverses high-docetaxel resistance developed in osteosarcoma cells. Anticancer Res 44(11): 4773-4778. DOI: 10.21873/anticanres.17303
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Hoffman RM
    : Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther 15(1): 21-31, 2015. DOI: 10.1517/14712598.2015.963050
    OpenUrlCrossRefPubMed
    1. Hoffman RM,
    2. Erbe RW
    : High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci USA 73(5): 1523-1527, 1976. DOI: 10.1073/pnas.73.5.1523
    OpenUrlAbstract/FREE Full Text
    1. Kaiser P
    : Methionine dependence of cancer. Biomolecules 10(4): 568, 2020. DOI: 10.3390/biom10040568
    OpenUrlCrossRefPubMed
    1. Wang Z,
    2. Yip LY,
    3. Lee JHJ,
    4. Wu Z,
    5. Chew HY,
    6. Chong PKW,
    7. Teo CC,
    8. Ang HY,
    9. Peh KLE,
    10. Yuan J,
    11. Ma S,
    12. Choo LSK,
    13. Basri N,
    14. Jiang X,
    15. Yu Q,
    16. Hillmer AM,
    17. Lim WT,
    18. Lim TKH,
    19. Takano A,
    20. Tan EH,
    21. Tan DSW,
    22. Ho YS,
    23. Lim B,
    24. Tam WL
    : Methionine is a metabolic dependency of tumor-initiating cells. Nat Med 25(5): 825-837, 2019. DOI: 10.1038/s41591-019-0423-5
    OpenUrlCrossRefPubMed
    1. Coalson DW,
    2. Mecham JO,
    3. Stern PH,
    4. Hoffman RM
    : Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells. Proc Natl Acad Sci USA 79(14): 4248-4251, 1982. DOI: 10.1073/pnas.79.14.4248
    OpenUrlAbstract/FREE Full Text
    1. Stern PH,
    2. Mecham JO,
    3. Wallace CD,
    4. Hoffman RM
    : Reduced free-methionine in methionine-dependent SV40-transformed human fibroblasts synthesizing apparently normal amounts of methionine. J Cell Physiol 117(1): 9-14, 1983. DOI: 10.1002/jcp.1041170103
    OpenUrlCrossRefPubMed
    1. Stern PH,
    2. Hoffman RM
    : Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 20(8): 663-670, 1984. DOI: 10.1007/BF02619617
    OpenUrlCrossRefPubMed
    1. Aoki Y,
    2. Han Q,
    3. Tome Y,
    4. Yamamoto J,
    5. Kubota Y,
    6. Masaki N,
    7. Obara K,
    8. Hamada K,
    9. Wang JD,
    10. Inubushi S,
    11. Bouvet M,
    12. Clarke SG,
    13. Nishida K,
    14. Hoffman RM
    : Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylation. Front Oncol 12: 1009548, 2022. DOI: 10.3389/fonc.2022.1009548
    OpenUrlCrossRefPubMed
    1. Yamamoto J,
    2. Inubushi S,
    3. Han Q,
    4. Tashiro Y,
    5. Sugisawa N,
    6. Hamada K,
    7. Aoki Y,
    8. Miyake K,
    9. Matsuyama R,
    10. Bouvet M,
    11. Clarke SG,
    12. Endo I,
    13. Hoffman RM
    : Linkage of methionine addiction, histone lysine hypermethylation, and malignancy. iScience 25(4): 104162, 2022. DOI: 10.1016/j.isci.2022.104162
    OpenUrlCrossRefPubMed
    1. Yamamoto J,
    2. Aoki Y,
    3. Inubushi S,
    4. Han Q,
    5. Hamada K,
    6. Tashiro Y,
    7. Miyake K,
    8. Matsuyama R,
    9. Bouvet M,
    10. Clarke SG,
    11. Endo I,
    12. Hoffman RM
    : Extent and instability of trimethylation of histone H3 lysine increases with degree of malignancy and methionine addiction. Cancer Genomics Proteomics 19(1): 12-18, 2022. DOI: 10.21873/cgp.20299
    OpenUrlAbstract/FREE Full Text
    1. Hoffman RM,
    2. Jacobsen SJ,
    3. Erbe RW
    : Reversion to methionine independence in simian virus 40-transformed human and malignant rat fibroblasts is associated with altered ploidy and altered properties of transformation. Proc Natl Acad Sci 76(3): 1313-1317, 1979. DOI: 10.1073/pnas.76.3.1313
    OpenUrlAbstract/FREE Full Text
    1. Hoffman RM,
    2. Jacobsen SJ,
    3. Erbe RW
    : Reversion to methionine independence by malignant rat and SV40-transformed human fibroblasts. Biochem Biophys Res Commun 82(1): 228-234, 1978. DOI: 10.1016/0006-291x(78)90600-9
    OpenUrlCrossRefPubMed
    1. Yamamoto J,
    2. Aoki Y,
    3. Han Q,
    4. Sugisawa N,
    5. Sun YU,
    6. Hamada K,
    7. Nishino H,
    8. Inubushi S,
    9. Miyake K,
    10. Matsuyama R,
    11. Bouvet M,
    12. Endo I,
    13. Hoffman RM
    : Reversion from methionine addiction to methionine independence results in loss of tumorigenic potential of highly-malignant lung-cancer cells. Anticancer Res 41(2): 641-643, 2021. DOI: 10.21873/anticanres.14815
    OpenUrlAbstract/FREE Full Text
    1. Hoffman RM
    : Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta 738: 49-87, 1984. DOI: 10.1016/0304-419x(84)90019-2
    OpenUrlCrossRefPubMed
    1. Abo Qoura L,
    2. Balakin KV,
    3. Hoffman RM,
    4. Pokrovsky VS
    : The potential of methioninase for cancer treatment. Biochim Biophys Acta Rev Cancer 1879(4): 189122, 2024. DOI: 10.1016/j.bbcan.2024.189122
    OpenUrlCrossRef
    1. Hoffman RM,
    2. Coalson DW,
    3. Jacobsen SJ,
    4. Erbe RW
    : Folate polyglutamate and monoglutamate accumulation in normal and SV40-transformed human fibroblasts. J Cell Physiol 109(3): 497-505, 1981. DOI: 10.1002/jcp.1041090316
    OpenUrlCrossRefPubMed
    1. Jacobsen SJ,
    2. Hoffman RM,
    3. Erbe RW
    : Regulation of methionine adenosyltransferase in normal diploid and simian virus 40-transformed human fibroblasts. J Natl Cancer Inst 65(6): 1237-44, 1980
    OpenUrlPubMed
    1. Ghergurovich JM,
    2. Xu X,
    3. Wang JZ,
    4. Yang L,
    5. Ryseck RP,
    6. Wang L,
    7. Rabinowitz JD
    : Methionine synthase supports tumour tetrahydrofolate pools. Nat Metab 3(11): 1512-1520, 2021. DOI: 10.1038/s42255-021-00465-w
    OpenUrlCrossRefPubMed
    1. Sullivan MR,
    2. Darnell AM,
    3. Reilly MF,
    4. Kunchok T,
    5. Joesch-Cohen L,
    6. Rosenberg D,
    7. Ali A,
    8. Rees MG,
    9. Roth JA,
    10. Lewis CA,
    11. Vander Heiden MG
    : Methionine synthase is essential for cancer cell proliferation in physiological folate environments. Nat Metab 3(11): 1500-1511, 2021. DOI: 10.1038/s42255-021-00486-5
    OpenUrlCrossRef
    1. Mecham JO,
    2. Rowitch D,
    3. Wallace C,
    4. Stern PH,
    5. Hoffman RM
    : The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 117(2): 429-434, 1983. DOI: 10.1016/0006-291x(83)91218-4
    OpenUrlCrossRefPubMed
    1. Stern PH,
    2. Wallace CD,
    3. Hoffman RM
    : Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 119(1): 29-34, 1984. DOI: 10.1002/jcp.1041190106
    OpenUrlCrossRefPubMed
    1. Tan Y,
    2. Xu M,
    3. Hoffman RM
    : Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells In Vitro. Anticancer Res 30(4): 1041-6, 2010
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Yamamoto J,
    2. Han Q,
    3. Inubushi S,
    4. Sugisawa N,
    5. Hamada K,
    6. Nishino H,
    7. Miyake K,
    8. Kumamoto T,
    9. Matsuyama R,
    10. Bouvet M,
    11. Endo I,
    12. Hoffman RM
    : Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells. Biochem Biophys Res Commun 533: 1034-1038, 2020. DOI:10.1016/j.bbrc.2020.09.108
    OpenUrlCrossRefPubMed
  65. ↵
    1. Stern PH,
    2. Hoffman RM
    : Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76(4): 629-639, 1986. DOI: 10.1093/jnci/76.4.629
    OpenUrlCrossRefPubMed
    1. Hoffman RM,
    2. Jacobsen SJ
    : Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc Natl Acad Sci USA 77(12): 7306-7310, 1980. DOI: 10.1073/pnas.77.12.7306
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Yano S,
    2. Li S,
    3. Han Q,
    4. Tan Y,
    5. Bouvet M,
    6. Fujiwara T,
    7. Hoffman RM
    : Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity. Oncotarget 5(18): 8729-8736, 2014. DOI: 10.18632/oncotarget.2369
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal Fibroblasts
SEI MORINAGA, QINGHONG HAN, KOHEI MIZUTA, BYUNG MO KANG, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA, ROBERT M. HOFFMAN
Anticancer Research Dec 2024, 44 (12) 5207-5213; DOI: 10.21873/anticanres.17347
Twitter logo Facebook logo Mendeley logo

Jump to section

Related Articles

Cited By...

More in this TOC Section

Keywords